Cyclooxygenase inhibition with acetylsalicylic acid unmasks a role for prostacyclin in erythropoietin-induced hypertension in uremic rats

Canadian Journal of Physiology and Pharmacology

Volumn 83, Issue 6, 2005, Pages 467-475

  Rodrigue, Marie Ève ^a   Lacasse M, Sonia ^a   Larivière, Richard ^a   Lebel, Marcel ^a  

^a NONE

Author keywords

Acetylsalicilic acid; Endothelin 1; Erythropoietin; Hypertension; Prostacyclin; Renal failure; Thromboxane

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ACETYLSALICYLIC ACID; CREATININE; ENDOTHELIN 1; ICOSANOID; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE; RECOMBINANT ERYTHROPOIETIN; THROMBOXANE A2; THROMBOXANE B2;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG EFFECT; DRUG INHIBITION; ENZYME INHIBITION; HEMATOCRIT; HYPERTENSION; KIDNEY CORTEX; KIDNEY FUNCTION; MALE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN SYNTHESIS; RAT; SYSTOLIC BLOOD PRESSURE; THORACIC AORTA; TISSUE LEVEL; UREMIA;

6-KETOPROSTAGLANDIN F1 ALPHA; ANIMALS; AORTA, THORACIC; ASPIRIN; BLOOD PRESSURE; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; EPOPROSTENOL; ERYTHROPOIETIN, RECOMBINANT; HUMANS; HYPERTENSION; KIDNEY CORTEX; KIDNEY FUNCTION TESTS; MALE; MESENTERIC ARTERIES; RATS; RATS, WISTAR; THROMBOXANE B2; UREMIA;

EID: 23844517058     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y05-032     Document Type: Article

References (50)

1. Abraham, P.A., and Macres, M.G. 1991. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J. Am. Soc. Nephrol. 2: 927-936.
2. Anagnostou, A., Liu, Z., Steiner, M., Chin, K., Lee, E.S., Kessimian, N., and Noguchi, C.T. 1994. Erythropoietin receptor mRNA expression in human endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 91: 3974-3978.
3. Bagnis, C., Beaufils, H., Jacquiaud, C., Adabra, Y., Jouanneau, C., Le Nahour, G., et al. 2001. Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol. Dial. Transplant. 16: 932-938.
4. Berglund, B., and Ekblom, B. 1991. Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men. J. Intern. Med. 229: 125-130.
5. Bode-Boger, S.M., Boger, R.H., Kuhn, M., Radermacher, J., and Frolich, J.C. 1996. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int. 50: 1255-1261.
6. Brochu, E., Lacasse, S., Larivière, R., Kingma, I., Grose, J.H., and Lebel, M. 1999. Differential effects of endothelin-1 antagonists on erythropoietin- induced hypertension in renal failure. J. Am. Soc. Nephrol. 10: 1440-1446.
7. Buckner, F.S., Eschbach, J.W., Haley, N.R., Davidson, R.C., and Adamson, J.W. 1990. Hypertension following erythropoietin therapy in anemic hemodialysis patients. Am. J. Hypertens. 3: 947-955.
8. Caravaca, F., Pizarro, J.L., Arrobas, M., Cubero, J.J., Garcia, M.C., and Perez-Miranda, M. 1994. Antiplatelet therapy and development of hypertension induced by recombinant human erythropoietin in uremic patients. Kidney Int. 45: 845-851.
9. Carlini, R.G., Dusso, A.S., Obialo, C.I., Alvarez, U.M., and Rothstein, M. 1993. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int. 43: 1010-1014.
10. de Nucci, G., Thomas, R., D'Orleans-Juste, P., Antunes, E., Walder, C., Warner, T.D., and Vane, J.R. 1988. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc. Natl. Acad. Sci. U.S.A. 85: 9797-9800.
11. del Basso, P., and Argiolas, L. 1995. Cardiopulmonary effects of endothelin-1 in the guinea pig: role of thromboxane A2. J. Cardiovasc. Pharmacol. 26(Suppl 3): S120-S122.
12. D'Orleans-Juste, P., Claing, A., Telemaque, S., Maurice, M.C., Yano, M., and Gratton, J.P. 1994. Block of endothelin-1-induced release of thromboxane A2 from the guinea pig lung and nitric oxide from the rabbit kidney by a selective ETB receptor antagonist, BQ-788. Br. J. Pharmacol. 113: 1257-1262.
13. Eggena, P., Willsey, P., Jamgotchian, N., Truckenbrod, L., Hu, M.S., Barrett, J.D., et al. 1991. Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. Am. J. Physiol. 261: E642-E646.
14. El Midaoui, A., Wu, R., and de Champlain, J. 2002. Prevention of hypertension, hyperglycemia and vascular oxidative stress by aspirin treatment in chronically glucose-fed rats. J. Hypertens. 20: 1407-1412.
15. Fischl, M., Galpin, J.E., Levine, J.D., Groopman, J.E., Henry, D.H., Kennedy, P., et al. 1990. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N. Engl. J. Med. 322: 1488-1493.
16. Fishbane, S., Ragolia, L., Palaia, T., Johnson, B., Elzein, H., and Maesaka, JK. 2004. Cytoprotection by darbepoetin/epoetin alfa in pig tubular and mouse mesangial cells. Kidney Int. 65: 452-458.
17. Garcia, D.L., Anderson, S., Rennke, H.G., and Brenner, B.M. 1988. Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc. Natl. Acad. Sci. U.S.A. 85: 6142-6146.
18. Jungers, P., Choukroun, G., Oualim, Z., Robino, C., Nguyen, A.T., and Man, N.K. 2001. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol. Dial. Transplant. 16: 307-312.
19. Kuriyama, S., Tomonari, H., and Hosoya, T. 1999. Antiplatelet therapy decreases the incidence of erythropoietin-induced hypertension in predialysis patients. Clin. Exp. Hypertens. 21: 213-222.
20. Lacasse, M.S., Kingma, I., Larivière, R., Grose, J.H., and Lebel, M. 1997. Uremia enhances the blood pressure response to erythropoietin. Clin. Exp. Hypertens. 19: 389-401.
21. Larivière, R., D'Amours, M., Lebel, M., Kingma I., Grose, J.H, and Caron, L. 1997. Increased immunoreactive endothelin-1 levels in blood vessels and glomeruli of rats with reduced renal mass. Kidney Blood Pressure Res. 20: 372-380.
22. Larivière, R., and Lebel, M. 2003. Endothelin-1 in chronic renal failure and hypertension. Can. J. Physiol. Pharmacol. 81: 607-621.
23. Larivière, R., Moreau, C., Rodrigue, M.E, and Lebel, M. 2004. Thromboxane blockade reduces blood pressure and renal failure progression independent of endothelin-1 in uremic rats. Prostaglandins, Leukotrienes Essent. Fatty Acids, 71: 103-109.
24. Lebel, M., and Grose, J.H. 1986. Abnormal renal prostaglandin production during the evolution of chronic nephropathy. Am. J. Nephrol. 6: 96-100.
25. Lebel, M., Grose, J.H., and Falardeau, P. 1989. Modulation of renal hemodynamics by renal eicosanoids during vasopressor infusions in man. Prostaglandins, Leukotrienes Essent. Fatty Acids, 35: 41-49.
26. Lebel, M., Kingma, I., Grose, J.H., and Langlois, S. 1995. Effect of recombinant human erythropoietin therapy on ambulatory blood pressure in normotensive and in untreated borderline hypertensive hemodialysis patients. Am. J. Hypertens. 8: 545-551.
27. Lebel, M., Kingma, I., Grose, J.H., and Langlois, S. 1998a. Hemodynamic and hormonal changes during erythropoietin therapy in hemodialysis patients. J. Am. Soc. Nephrol. 9: 97-104.
28. Lebel, M., Lacasse, M.S., Larivière, R., Kingma, I., and Grose, J.H. 1998b. Plasma and blood vessel endothelin-1 concentrations in hypertensive uremic rats treated with erythropoietin. Clin. Exp. Hypertens. 20: 939-951.
29. Livio, M., Denigni, A., Zoja, C., Begnis, R., Morelli, C., Rossini, M., et al. 1989. Differential inhibition by aspirin of platelet thromboxane and renal prostaglandins in the rat. J. Pharmacol. Exp. Ther. 248: 334-341.
30. Ludwig, H., Fritz, E., Kotzmann, H., Hocker, P., Gisslinger, H., and Barnas, U. 1990. Erythropoietin treatment of anemia associated with multiple myeloma. N. Engl. J. Med. 322: 1693-1699.
31. Moreau, C., Larivière, R., Kingma, I., Grose, J.H., and Lebel, M. 2000. Chronic nitric oxide inhibition aggravates hypertension in erythropoietin-treated renal failure rats. Clin. Exp. Hypertens. 22: 663-674.
32. Ni, Z., Wang, X.Q., and Vaziri, N.D. 1998. Nitric oxide metabolism in erythropoietin-induced hypertension: effect of calcium channel blockade. Hypertension, 32: 724-729.
33. Pincus, T., Olsen, N.J., Russell, I.J., Wolfe, F., Harris, E.R., Schnitzer, T.J., et al. 1990. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am. J. Med. 89: 161-168.
34. Prins, B.A, Hu, R.M., Nazario, B., Pedram, A., Frank, H.J., Weber, M.A., and Levin, E.R. 1994. Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J. Biol. Chem. 269: 11938-11944.
35. Purkerson, M.L., Joist, J.H., Yates, J., Valdes, A., Morrison, A., and Klahr, S. 1985. Inhibition of thromboxane synthesis ameliorates the progressive kidney disease of rats with subtotal renal ablation. Proc. Natl. Acad. Sci. U.S.A. 82: 193-197.
36. Rahmani, M.A., David, V., Huang, M., and DeGray, G. 1998. Effect of aspirin on the contractility of aortic smooth muscle and the course of blood pressure development in male spontaneously hypertensive rats. Artery, 23: 37-55.
37. Rodrigue, M.E., Moreau, C., Larivière, R., and Lebel, M. 2003. Relationship between eicosanoids and endothelin-1 in the pathogenesis of erythropoietin-induced hypertension in uremic rats. J. Cardiovasc. Pharmacol. 41: 388-395.
38. Roth, D., Smith, R.D., Schulman, G., Steinman, T.I., Hatch, F.E., Rudnick, M.R., et al. 1994. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am. J. Kidney Dis. 24: 777-784.
39. Ruiz-Ortega, M., Gomez-Garre, D., Alcazar, R., Palacios, I., Bustos, C., Gonzalez, S., et al. 1994. Involvement of angiotensin II and endothelin in matrix protein production and renal sclerosis. J. Hypertens. 12 (Suppl): S51-S58.
40. Schirner, M., and Taube, C. 1993. Different effects of aspirin on blood pressure of spontaneously hypertensive rats (SHR) with high and spontaneously low levels of blood pressure. Br. J. Pharmacol. 109: 900-901.
41. + exchange, c-fos expression, and mitogenesis in rat mesangial cells. J. Clin. Invest. 83: 708-712.
42. Taddei, S., and Vanhoutte, P.M. 1993. Role of endothelium in endothelin-evoked contractions in the rat aorta. Hypertension, 21: 9-15.
43. 2 biosynthesis in rat vascular smooth muscle cells. Biochem. Pharmacol. 40: 2713-2717.
44. Tomida, T., Numaguchi, Y., Matsui, H., Toki, Y., Ito, T., Okumura, K., and Hayakawa, T. 2001. Altered expression of prostacyclin synthase in a subset of the thick ascending limb cells and mesangial cells in 5/6-nephrectomized rats. Hypertens. Res. 24: 411-419.
45. Torralbo, A., Blanco, J., Fontanellas, A., Herrero, J.A., Cruceyra, A., Gonzalez-Lopez, P., and Barrientos, A. 1996. Long-term erythropoietin in rats with reduced renal mass. Nephron, 73: 280-285.
46. Vaziri, N.D., Zhou, X.J., Naqvi, F., Smith, J., Oveisi, F., Wang, Z.Q., and Purdy, R.E. 1996. Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am. J. Physiol. 271: E113-E122.
47. Voisin, E.M., Ruthsatz, M., Collins, J.M., and Hoyle, P.C. 1990. Extrapolation of animal toxicity to humans: interspecies comparisons in drug development. Regul. Toxicol. Pharmacol. 12: 107-116.
48. Wu, R., Lamontagne, D., and de Champlain, J. 2002. Antioxidative properties of acetylsalicylic Acid on vascular tissues from normotensive and spontaneously hypertensive rats. Circulation, 105: 387-392.
49. Yang, C.W., Li, C., Jung, J.Y., Shin, S.J., Choi, B.S., Lim, S.W., et al. 2003. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J. 17: 1754-1755.
50. Zoja, C., Benigni, A., Livio, M., Bergamelli, A., Orisio, S., Abbate, M., et al. 1989. Selective inhibition of platelet thromboxane generation with low-dose aspirin does not protect rats with reduced renal mass from the development of progressive disease. Am. J. Pathol. 134: 1027-1038.